Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET

Investors will be able to hear Intelligent Bio Solutions discuss its FDA 510(k) submission, clinical data and ex-U.S. commercial progress in a live webcast.

Rhea-AI Summary

Intelligent Bio Solutions (INBS) will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET.

The moderated discussion will feature President and CEO Harry Simeonidis and Vice President of Product Development Peter Passaris. Topics include the company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, supporting clinical data, the FDA review process, and commercial progress outside the United States. The event will be accessible via live webcast through an online registration link, with a replay available on the company’s investor relations website after the session.

Key Terms

510(k)

1 terms

510(k) regulatory

"FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET.

The moderated discussion will feature Harry Simeonidis, President and CEO, and Peter Passaris, Vice President of Product Development. Topics will include the Company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, the supporting clinical data, the FDA review process, and the Company’s commercial progress outside the United States.

Event Details

• Date: Thursday, September 24, 2026
• Time: 4:30 p.m. ET
• Format: Virtual fireside chat, followed by a live Q&A session
• Webcast Registration: https://us02web.zoom.us/webinar/register/WN_vWXs5KeQSYCxSxhmR5_bVQ

A live webcast of the event will be available through the registration link above. A replay of the presentation will be made available on the Company’s investor relations website following the event.

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

Company Contact 
Intelligent Bio Solutions Inc.   
info@ibs.inc

Investor & Media Contact  
Valter Pinto, Managing Director   
KCSA Strategic Communications   
PH: (212) 896-1254   
INBS@kcsa.com